Other secondary efficacy outcomes at day 183
| . | Ravulizumab (n = 96) . | Eculizumab (n = 95) . | ||
|---|---|---|---|---|
| Total number of packed red blood cell units transfused, mean (SD) | — | 4.3 (4.76)† | — | 3.4 (3.01)‡ |
| Patients with major adverse vascular events, n (%) | — | 0 (0) | — | 0 (0) |
| . | Ravulizumab (n = 96) . | Eculizumab (n = 95) . | ||
|---|---|---|---|---|
| Total number of packed red blood cell units transfused, mean (SD) | — | 4.3 (4.76)† | — | 3.4 (3.01)‡ |
| Patients with major adverse vascular events, n (%) | — | 0 (0) | — | 0 (0) |
| . | Baseline* . | Day 183 . | Baseline* . | Day 183 . |
|---|---|---|---|---|
| Clinical manifestations of PNH, n (%) | ||||
| Fatigue | 29 (30.2) | 42 (43.8) | 38 (40) | 36 (37.9) |
| Abdominal pain | 5 (5.2) | 5 (5.2) | 6 (6.3) | 12 (12.6) |
| Dyspnea | 6 (6.3) | 6 (6.3) | 10 (10.5) | 17 (17.9) |
| Dysphagia | 2 (2.1) | 5 (5.2) | 2 (2.1) | 5 (5.2) |
| Chest pain | 0 (0) | 2 (2.1) | 1 (1.1) | 5 (5.2) |
| Hemoglobinuria | 4 (4.2) | 8 (8.3) | 7 (7.4) | 9 (9.5) |
| Erectile dysfunction§ | 5 (10.0) | 6 (12.0) | 7 (14.6) | 6 (12.5) |
| . | Baseline* . | Day 183 . | Baseline* . | Day 183 . |
|---|---|---|---|---|
| Clinical manifestations of PNH, n (%) | ||||
| Fatigue | 29 (30.2) | 42 (43.8) | 38 (40) | 36 (37.9) |
| Abdominal pain | 5 (5.2) | 5 (5.2) | 6 (6.3) | 12 (12.6) |
| Dyspnea | 6 (6.3) | 6 (6.3) | 10 (10.5) | 17 (17.9) |
| Dysphagia | 2 (2.1) | 5 (5.2) | 2 (2.1) | 5 (5.2) |
| Chest pain | 0 (0) | 2 (2.1) | 1 (1.1) | 5 (5.2) |
| Hemoglobinuria | 4 (4.2) | 8 (8.3) | 7 (7.4) | 9 (9.5) |
| Erectile dysfunction§ | 5 (10.0) | 6 (12.0) | 7 (14.6) | 6 (12.5) |